Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$15.63 +6.0%	$14.33	$8.03 ▼ $17.75	$1.87B	1.84	2.15 million shs	2.93 million shs
NUVL Nuvalent	$78.24 +2.1%	$78.91	$55.53 ▼ $113.51	$5.62B	1.3	546,505 shs	284,968 shs
RYTM Rhythm Pharmaceuticals	$97.86 +1.5%	$77.27	$43.57 ▼ $99.04	$6.50B	2.38	672,005 shs	733,610 shs
TGTX TG Therapeutics	$27.87 +2.8%	$35.72	$20.39 ▼ $46.48	$4.42B	1.95	2.52 million shs	2.70 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+3.88%	-3.79%	-1.80%	+8.38%	+55.32%
NUVL Nuvalent	+2.21%	-2.56%	-5.34%	+7.87%	+6.18%
RYTM Rhythm Pharmaceuticals	+2.28%	+8.91%	+11.26%	+68.40%	+116.86%
TGTX TG Therapeutics	+2.77%	-4.51%	-26.86%	-18.80%	+31.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.5183 of 5 stars	3.4	3.0	0.0	2.1	1.7	0.6
NUVL Nuvalent	3.1031 of 5 stars	4.5	1.0	0.0	2.3	3.3	0.0
RYTM Rhythm Pharmaceuticals	3.3973 of 5 stars	2.5	2.0	4.3	2.6	0.8	0.6
TGTX TG Therapeutics	4.1679 of 5 stars	3.4	0.0	3.5	3.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	26.68% Upside
NUVL Nuvalent	3.09	Buy	$119.60	52.86% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$101.57	3.79% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	65.95% Upside

Current Analyst Ratings Breakdown

Latest ARQT, RYTM, NUVL, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
8/7/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $100.00
8/6/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$119.00 ➝ $120.00
8/6/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$130.00 ➝ $135.00
8/5/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $109.00
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	9.54	N/A	N/A	$1.16 per share	13.47
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.09 per share	N/A
RYTM Rhythm Pharmaceuticals	$156.29M	41.59	N/A	N/A	($0.18) per share	-543.67
TGTX TG Therapeutics	$454.07M	9.74	$0.13 per share	219.99	$1.74 per share	16.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	N/A
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	8/14/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$3.01	N/A	N/A	N/A	-117.13%	-1,831.43%	-48.33%	N/A
TGTX TG Therapeutics	$23.38M	$0.37	75.32	27.87	N/A	13.31%	26.05%	9.58%	N/A

Latest ARQT, RYTM, NUVL, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.66	-$0.75	-$0.09	-$0.75	$43.72 million	$48.50 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
NUVL Nuvalent	N/A	13.57	13.57
RYTM Rhythm Pharmaceuticals	N/A	2.79	2.64
TGTX TG Therapeutics	0.89	3.86	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
NUVL Nuvalent	97.26%
RYTM Rhythm Pharmaceuticals	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
NUVL Nuvalent	10.20%
RYTM Rhythm Pharmaceuticals	6.10%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.90 million	108.63 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
RYTM Rhythm Pharmaceuticals	140	66.42 million	62.37 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

ARQT, RYTM, NUVL, and TGTX Headlines

Recent News About These Companies

Persistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 13 at 7:05 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment Board

August 13 at 5:44 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LP

August 13 at 4:57 AM | marketbeat.com

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10 at 7:35 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10 at 3:50 AM | marketbeat.com

What is B. Riley's Estimate for TG Therapeutics Q3 Earnings?

August 9, 2025 | americanbankingnews.com

TG Therapeutics files automatic mixed securities shelf

August 9, 2025 | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8, 2025 | gurufocus.com

What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

August 8, 2025 | marketbeat.com

What is B. Riley's Forecast for TG Therapeutics Q4 Earnings?

August 8, 2025 | americanbankingnews.com

FY2025 EPS Estimate for TG Therapeutics Reduced by Analyst

August 8, 2025 | americanbankingnews.com

B. Riley Has Bullish Outlook for TG Therapeutics Q4 Earnings

August 7, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings

August 7, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $43.80 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook

August 6, 2025 | msn.com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

August 6, 2025 | msn.com

Federated Hermes Inc. Sells 64,385 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

August 6, 2025 | marketbeat.com

Investors Purchase High Volume of Call Options on TG Therapeutics (NASDAQ:TGTX)

August 6, 2025 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Gap Down Following Weak Earnings

August 6, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

August 5, 2025 | insidermonkey.com

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

August 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, RYTM, NUVL, and TGTX Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$15.63 +0.89 (+6.04%)

Closing price 04:00 PM Eastern

Extended Trading

$15.62 -0.01 (-0.03%)

As of 07:58 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Nuvalent NASDAQ:NUVL

$78.24 +1.63 (+2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$78.28 +0.04 (+0.04%)

As of 05:33 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$97.86 +1.40 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$97.75 -0.11 (-0.11%)

As of 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$27.87 +0.75 (+2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$27.92 +0.05 (+0.20%)

As of 07:26 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time